Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Qiagen enters the T-cell testing fray
At least two groups have posted early data on T-cell tests for Covid-19; now Qiagen has licensed tech to make its own.
Another complement factor enters the deal-making frame
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
Healthineers collaboration aims to link antibodies to immunity
The effort has implications for international travel and allocating vaccines – but the precise quantitative tests necessary for this do not, as yet, exist.
Seattle benefits from Merck's long shot
Merck's move on a target that has attracted little attention – Liv-1 – means future data readouts are now eagerly awaited.
Boehringer hopes schizophrenia apps will Click into place
Licensing deal could enable bundling of antipsychotics with management technology.
Abbvie looks east for CD47
Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.
